Descrizione del progetto
L’IA per il monitoraggio della congestione dei fluidi polmonari
L’insufficienza cardiaca (IC) è una delle cause più frequenti di ospedalizzazione e morte prematura in tutto il mondo. I pazienti che sopravvivono all’IC e tornano a casa devono essere sottoposti a monitoraggio continuo, in modo che eventuali complicanze dovute alla congestione dei fluidi polmonari vengano immediatamente trattate. Sfortunatamente, queste sono spesso diagnosticate molto tardi. Il progetto ReDS, finanziato dall’UE, sta sviluppando un dispositivo medico che consente un monitoraggio facile e rapido della congestione polmonare a livello domiciliare. Non è invasivo, ed è connesso a una piattaforma basata sull’intelligenza artificiale che gestisce i dati raccolti e li invia automaticamente al centro di cura. Uno speciale algoritmo aiuta il medico a prescrivere un trattamento adeguato in base alle condizioni del paziente.
Obiettivo
Heart failure (HF) is one of the main causes of mortality and hospitalization worldwide, affecting around 26M people globally, and the most common cause of hospitalization for people over 65. Lung fluid congestion is one of the main HF-related clinical conditions, which leads to a vicious cycle of repeated hospitalizations of HF patients. Strikingly, 1 in 4 patients are readmitted to the hospital within 30 days, and 1 in 2 patients within 6 months. The key challenge is to enable early detection, continuous monitoring and timely treatment of symptoms before the patient undergoes respiratory distress. In fact, current lung fluid monitoring practices are mostly inaccurate and inefficient, enabling detection only at very advanced stages, when symptoms cannot be prevented by simply changing the medication.
Sensible introduces ReDS™, a non-invasive home monitoring system for lung fluid congestion in HF patients. The monitoring procedure can be performed by the patient at home in just 90 seconds. The results are processed by an Artificial Intelligence (AI)-driven patient management platform and sent automatically to the physician. The unique proprietary AI algorithm supports physicians in identifying the best treatment based on each patients’ needs and general health status. ReDS™ is the first solution that enables accurate, remote monitoring and management of fluid congestion in HF patients after discharge.
During the phase 1 feasibility study, Sensible will define a minimum viable product, establish a sound go-to-market strategy and supply chain, and draft further development plans. During the second phase of the innovation project, Sensible will optimize the device engineering for home use, optimize the AI algorithm, scale-up device manufacturing and perform clinical validation with partner hospitals.
Campo scientifico
- natural sciencescomputer and information sciencesartificial intelligence
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologyradar
- medical and health sciencesclinical medicinecardiology
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
4059300 NETANYA
Israele
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.